sellNotable cluster of 5
Adrian Rawcliffe sold $35k of ADAPY
Chief Executive Officer at Adaptimmune Therapeutics PLC. 59,569 shares at an average of $0.58, traded Jan 13, 2025, filed Jan 15, 2025.
Warning score
66Value
$35k
59,569 shares
Holdings after
41,582
-196% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +6Trade size$35k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-003775, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 13, 2025 | SOpen-market sale American Depositary Shares representing Ordinary Shares | -12,539 | $0.59 | $7,372 | 17,801 | Jan 15, 2025 |
| Jan 13, 2025 | SOpen-market sale American Depositary Shares representing Ordinary Shares | -17,934 | $0.59 | $11k | 25,711 | Jan 15, 2025 |
| Jan 15, 2025 | SOpen-market sale American Depositary Shares representing Ordinary Shares | -29,096 | $0.57 | $17k | 41,582 | Jan 15, 2025 |
Related signals
Other insiders at Adaptimmune Therapeutics PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Adaptimmune Therapeutics PLC | Gavin Wood Chief Financial Officer | $950 96,000 shares | -100% | |
| 40Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $2,091 207,000 shares | -17% | |
| 56Moderate | Adaptimmune Therapeutics PLC | Ali Behbahani director | $229k 19,500,000 shares | -100% | |
| 47Moderate | ADAPYsell Adaptimmune Therapeutics PLC | EcoR1 Capital, LLC owner | $6.9M 64,052,538 shares | -39% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Adrian Rawcliffe Chief Executive Officer | $18k 30,601 shares | -41% | |
| 45Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $3,243 5,584 shares | -43% | |
| 55Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $11k 19,542 shares | -193% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.